patent.fyi
Applications  /  US 2026/0355321
United States Patent Application Publication

US 2026/0355321 A1

Published
Nov 12, 2026
Filed
Jun 17, 2026
Earliest date on the face
May 2, 2011
Classification
A61K 47/26
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Subcutaneous third dose

What ifWhat if the third dose uses 108 mg injected subcutaneously at week 6?
Claim language“a third dose of 300 mg”

The first two 300 mg doses enter the bloodstream by intravenous infusion at weeks 0 and 2. At week 6, a prefilled syringe deposits 108 mg into subcutaneous tissue, where the antibody enters systemic circulation through lymphatic absorption.

1.2Four week maintenance interval

What ifWhat if maintenance doses recur every 4 weeks?
Claim language“every 8 weeks”

The first maintenance infusion contains 300 mg and occurs 8 weeks after the third induction dose. Subsequent 300 mg infusions occur at 28-day intervals, reducing the time for serum antibody concentration to fall between doses.

1.3Higher steady state trough

What ifWhat if the measured mean steady state trough is 30 μg/mL?
Claim language“5 μg/mL to 25 μg/mL”

A quantitative immunoassay measures serum samples collected immediately before several maintenance infusions after concentrations stabilize. In a pharmacokinetic study, a shorter infusion interval raises the trough by reducing the time available for antibody clearance between doses.

1.4Treatment of chronic pouchitis

What ifWhat if the treated condition is chronic pouchitis in a surgically constructed ileal pouch?
Claim language“Crohn's disease or ulcerative colitis”

The antibody binds α4β7 integrin on circulating lymphocytes and inhibits its interaction with an endothelial adhesion molecule expressed in gut tissue. This reduces lymphocyte trafficking to the inflamed pouch mucosa.

1.5Stabilized IgG4 constant region

What ifWhat if the antibody uses an IgG4 heavy-chain constant region?
Claim language“an IgG1 isotype”

The heavy-chain variable domains attach to IgG4 constant domains, and the light chains pair with the resulting heavy chains to form a bivalent antibody. A serine-to-proline substitution at hinge position 228 reduces exchange of heavy-chain and light-chain pairs between antibody molecules.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Outpatient induction with home maintenance

An outpatient infusion center administers the 300 mg intravenous induction doses at weeks 0, 2, and 6. A home infusion service administers the same antibody every 8 weeks beginning at week 14, using a portable infusion pump and pharmacy-prepared bags. A visiting nurse draws preinfusion serum samples and sends them to a laboratory for trough concentration measurement.

Component substitution

Trehalose as the formulation sugar

Trehalose serves as the non-reducing sugar in place of sucrose in a freeze-dried formulation of the humanized IgG1 anti-α4β7 antibody. The liquid fill combines the antibody, trehalose, and histidine before freeze-drying in single-dose vials. Pharmacy staff reconstitute the dried material with sterile water and dilute the prescribed dose in an intravenous infusion bag.

Parameter or scale variation

Two vials per infusion dose

Single-dose vials each contain 150 mg of the freeze-dried humanized IgG1 anti-α4β7 antibody formulated with a non-reducing sugar and an amino acid. Pharmacy staff reconstitute two vials and transfer a combined 300 mg into one intravenous infusion bag. The bag supplies one administration at each induction or maintenance visit.

Combination with existing systems

Barcode verification at infusion visits

A barcode medication administration system links each prepared infusion bag to a patient identifier, prescription, and preparation record. The nurse scans the patient's wristband and the bag label before connecting the intravenous line. The system compares both scans with the active order and records the administration time after the nurse confirms delivery.

Concurrent stool marker monitoring

A stool calprotectin testing service operates alongside serum antibody testing during maintenance. At a scheduled maintenance visit, the clinic collects a preinfusion serum sample and accepts a stool specimen for laboratory analysis. The clinical record displays the stool calprotectin result and serum antibody concentration alongside infusion dates so clinicians can review both trends.

Automated or data-driven variant

Automated review of maintenance troughs

A laboratory interface delivers serum antibody concentrations and specimen collection times to a monitoring application. The application pairs results with infusion records and accepts samples collected during maintenance on the scheduled infusion day before the recorded infusion start. It calculates the mean of samples marked as steady state and flags values outside 5 to 25 μg/mL for clinician review.

Specific version of a part

Pump controlled induction infusions

A lyophilized preparation containing the antibody, a non-reducing sugar, and an amino acid is reconstituted with sterile water. At weeks 0, 2, and 6, a 300 mg dose is diluted in an isotonic saline bag and delivered intravenously by a volumetric pump over 30 minutes.

Maintenance visits on fixed dates

The infusion calendar places the first maintenance visit on day 98, which is 56 days after the third induction dose on day 42. A 300 mg intravenous dose is administered at that visit and every 56 days thereafter.

Predose serum concentration assay

Serum is collected immediately before each of three consecutive maintenance infusions after steady state is reached. A calibrated ligand-binding immunoassay quantifies the antibody in each sample, and the arithmetic mean is compared with the 5 to 25 μg/mL interval.

Dual cassette antibody expression

One expression cassette encodes the light chain with LCDR1 through LCDR3 corresponding to sequence identifiers 11 through 13. A second cassette encodes the heavy chain with HCDR1 through HCDR3 corresponding to sequence identifiers 8 through 10, and mammalian cells secrete the assembled antibody.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2007/0025961 A1
Published
Feb 1, 2007
Filed
May 6, 2004
Class
A61K 39/395
Document BUS 2009/0258001 A1
Published
Oct 15, 2009
Filed
Jun 5, 2007
Class
A61K 39/395
Claim 1
Document A
Document B
1.1an induction phase comprising, intravenously administering an initial dose of 300 mg of a humanized anti-α4β7 antibody to the human patient, and intravenously administering a second dose of 300 mg of the humanized anti-α4β7 antibody to the human patient 2 weeks after the initial dose, and intravenously administering a third dose of 300 mg of the humanized anti-α4β7 antibody to the human patient 6 weeks after the initial dose, and
Besides, dosage of the composition according to the present invention is varied depending on the age, conditions and the like of a patient, but the humanized antibodies are administered in a dose of from 0.2 to 20 mg/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently 1 to 3 times in a week or in 2 or 3 weeks.
A · US 2007/0025961 A1 · ¶ 71
TRX4 antibody, which is an anti-CD3 antibody having a humanized heavy chain and a chimeric light chain, and has an aglycosylated Fc region, in which Asn297 has been mutated to Ala297, was administered intravenously at a dose of 0.5 mg, or about 7.1 μg/kg, for three consecutive days to each of three patients diagnosed with Type I diabetes.
B · US 2009/0258001 A1 · ¶ 90
1.2a maintenance phase comprising, intravenously administering a dose of 300 mg of the humanized anti-α4β7 antibody to the human patient every 8 weeks beginning 8 weeks after the third dose,
The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently 1 to 3 times in a week or in 2 or 3 weeks.
A · US 2007/0025961 A1 · ¶ 71
1.3wherein the human patient has a mean steady state trough serum concentration of 5 μg/mL to 25 μg/mL of the humanized anti-α4β7 antibody during the maintenance phase,
1.4wherein the IBD is Crohn's disease or ulcerative colitis,
1.5wherein the humanized anti-α4β7 antibody is an IgG1 isotype, and
An example of such an antibody is the hOKT3γ1 (Ala-Ala) antibody, which is a humanized anti-CD3 monoclonal antibody that contains the binding region of the murine monoclonal antibody OKT3 (U.S. No. 4,658,019) on a human IgG1, and wherein amino acid residues Leu234 Leu235 are replaced with alanine residues.
B · US 2009/0258001 A1 · ¶ 34
1.6wherein the humanized anti-α4β7 antibody comprises a light chain comprising SEQ ID NO: 11 (LCDR1), SEQ ID NO: 12 (LCDR2), and SEQ ID NO: 13 (LCDR3), and a heavy chain comprising SEQ ID NO: 8 (HCDR1), SEQ ID NO: 9 (HCDR2), and SEQ ID NO: 10 (HCDR3).
DNA that encodes the sequence of the polypeptide of variable region of immunoglobulin light and heavy chain of the human monoclonal antibody in this invention can be obtained from cDNA library by conventional methods.
A · US 2007/0025961 A1 · ¶ 78
In one embodiment, the anti-CD3 antibody includes a humanized heavy chain in which the complementarity determining regions, or CDRs, of the variable region of the heavy chain are rat CDRs and the remainder of the heavy chain is human, and a chimeric light chain in which the variable region is a rat variable region and the constant region is a human constant region, except that amino acid residues 1, 2, 3, 4, and 7 of the rat variable region have been mutated.
B · US 2009/0258001 A1 · ¶ 32

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, because the respective methods have problems in the points of a residual of antigenicity, difficulty of establishing human antibody producing lines, decrease of capacity of antibody production during cell culture and so on, it is strongly desired to develop a method for establishing human antibodies easily and efficiently by the other procedure.
A · US 2007/0025961 A1 · ¶ 7
However, even if autologous lymphocytes propagated with anti-CD3 antibodies and interleukin 2 are effective to an antitumor effect or a viral infection in a congenital immunodeficiency patient, it does not mean a stage in which satisfactory effect can be necessarily expected with it.
A · US 2007/0025961 A1 · ¶ 5
In one embodiment, this invention relates to the administration of anti-CD3 antibodies or fragments thereof, to treat an autoimmune disease, such as diabetes or psoriasis, at reduced dosage levels.
B · US 2009/0258001 A1 · ¶ 2
In one embodiment, the disease is an established, spontaneous, and ongoing autoimmune disease.
B · US 2009/0258001 A1 · ¶ 11
Cite aspatent.fyi, US 2026/0355321 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355321/, SHA-256 096c4ec25d0d67232e55b536e1f96dd79801cb726ed262794681884c49f042af
First published
Permanent addresshttps://patent.fyi/US20260355321/
Content fingerprint (SHA-256)096c4ec25d0d67232e55b536e1f96dd79801cb726ed262794681884c49f042af
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi